– Bambusa’s lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 inflammatory skin diseases –

– BBT001 achieved rapid, deep, and sustained effects on key biomarkers of interest in AD for at least 12 weeks, including reduction of TARC and inhibition of pSTAT6 –

– BBT001 was well tolerated across all doses in both the single- and multiple-ascending dose cohorts of the Phase 1 trial –

– BBT001 exhibited a consistent half-life of approximately 33 days in Phase 1 trial supporting prolonged maintenance dosing interval compared to currently approved medicines in AD –

– Bambusa plans to disclose data from the ongoing placebo-controlled, 4-week Phase 1b/2a trial of BBT001 in patients with moderate to severe atopic dermatitis in the middle of 2026 –

BOSTON, April 1, 2026 /PRNewswire/ — Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation bispecific antibodies for immunology and inflammation, today announced it presented data from the multiple ascending dose (MAD) cohorts of the Phase 1 trial evaluating BBT001 in healthy volunteers at the 2026 American Academy of Dermatology Annual Meeting (AAD 2026) in Denver, Colorado.

The AAD 2026 clinical poster of BBT001 titled, “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT001, a Novel Bispecific IL-4Rα/IL-31 Antibody: Results from the Single- and Multiple-Ascending Dose Portions of a Phase 1 Study of Healthy Volunteers and Patients with Atopic Dermatitis” highlighted the following data:

• % change in Thymus and Activation-Regulated Chemokine (TARC). TARC levels in the blood correlate strongly with disease severity in AD (e.g. Eczema Area and Severity Index [EASI] score).
  • BBT001 demonstrated unprecedented dose-dependent, rapid, deep, and sustained reduction in TARC compared to baseline after multiple doses.
• % change in phosphorylated STAT6 (pSTAT6). pSTAT6 is a key downstream mediator of type 2 inflammation in atopic dermatitis.
  • BBT001 achieved rapid, complete, and sustained inhibition of pSTAT6 for at least 12 weeks after multiple doses.
• Pharmacokinetics (PK): BBT001 exhibited prolonged PK with a half-life of approximately 33 days at or above target exposure after multiple doses, consistent with the PK observed in the SAD cohorts.
• Safety and Tolerability: BBT001 was well-tolerated across all doses in the SAD cohorts (previously presented at EADV 2025) and MAD cohorts with a clean safety profile observed in the trial.
• Immunogenicity: The incidence of anti-drug antibodies (ADA) was low and showed no apparent impact on safety or PK.

“We were excited to highlight the data from our BBT001 clinical program for the first time at the American Academy of Dermatology Annual Meeting,” said Thang Ho, Ph.D., Chief Scientific Officer at Bambusa Therapeutics. “The Phase 1 MAD data confirm the earlier clinical evidence achieved in the SAD portion of the trial, and further support BBT001’s potential to become a best-in-disease biologic to treat atopic dermatitis. Importantly, these data continue to support the potential for BBT001 to deliver faster onset and improved clinical outcomes for patients with atopic dermatitis compared to currently approved medicines.”

“Following our team’s rapid execution of the BBT001 Phase 1 trial including the presentation of the positive data from all doses and cohorts, we now look forward to disclosing data from our ongoing BBT001 4-week Phase 1b/2a trial in patients with atopic dermatitis in the middle of this year,” said Shanshan Xu, M.D., Ph.D., Founder & Chief Executive Officer of Bambusa Therapeutics. “The possibility to generate our first proof-of-concept clinical data in patients with AD is a significant milestone for Bambusa Therapeutics, and it has the exciting potential to give us the first look of how BBT001 could redefine the standard of care for people with atopic dermatitis in the future.”

BBT001 is currently being evaluated in multiple ongoing Phase 1b/2a trials in patients with moderate to severe AD. The Company expects to disclose data from the ongoing 4-week placebo-controlled trial in the middle of 2026.

About the Phase 1 SAD/MAD trial of BBT001

BBT001-001 is a randomized, placebo-controlled, single- and multiple-ascending-dose study in healthy volunteers and adults with moderate to severe atopic dermatitis. The trial is evaluating safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary clinical activity.

About BBT001

BBT001 is Bambusa Therapeutics’ lead clinical program and a first-in-class, multi-targeting, half-life extended bispecific antibody engineered to block both IL-4Rα and IL-31 signaling. By addressing type 2 inflammation and directly targeting the pathways that drive itch, BBT001 is designed to provide faster and more durable relief for patients with atopic dermatitis and other inflammatory skin diseases. The molecule has demonstrated a favorable safety profile and strong pharmacokinetics in healthy volunteers, supporting its advancement into multiple clinical trials in patients, including AD and chronic spontaneous urticaria (CSU).

About Bambusa Therapeutics

Bambusa Therapeutics is a clinical-stage biotechnology company developing a portfolio designed to transform care across a wide spectrum of chronic diseases. Powered by an innovative antibody engineering platform featuring half-life extension and high-concentration subcutaneous delivery, Bambusa’s vision is to deliver transformative medicines for patients across every stage of life — setting a new pace for the next era of I&I therapeutics.

• BBT001 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-31 with best-in-disease potential. It is currently in Phase 1b/2a proof-of-concept development for atopic dermatitis and other type 2 inflammatory skin diseases.
  
  
• BBT002 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-5 with platform-in-a-molecule potential. It is currently in Phase 1b proof-of-concept development for type 2 inflammatory disorders including COPD, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, and food allergy.
• BBT003 and BBT004 are preclinical programs focused on gastroenterology and rheumatology, respectively.

SHENZHEN, China, April 1, 2026 /PRNewswire/ — MicroAlgo Inc. (NASDAQ: MLGO), (the “Company”), a leading developer and application provider of bespoke central processing algorithms, today announced its financial results for the year ended December 31, 2025.

Financial Highlights 2025

The Company’s net profit for 2025 was RMB 127.56 million (USD 18.15 million), representing a substantial increase of 143.5% compared with the same period of the prior year, demonstrating the Company’s strong profitability.

Diluted earnings per share for 2025 were RMB 14.87 (USD 2.12), compared with RMB 3.99 in 2024, representing an increase of 272.7%.

Total shareholders’ equity more than doubled, reaching RMB 2,321.80 million (USD 330.33 million) as of December 31, 2025, representing an increase of 122.8% from RMB 1,041.93 million at the end of 2024.

Operating Performance

The Company continued to focus on its core central processing algorithm services and is committed to providing high-quality solutions for internet advertising customers. In 2025, the Company achieved operating revenue of RMB 422.05 million (USD 60.05 million), gross profit of RMB 108.82 million (USD 15.48 million), with a gross margin of 25.8%.

Operating expenses decreased significantly by 35.3% year-on-year, mainly due to the successful completion of major algorithm development projects and strict cost control measures. Operating profit amounted to RMB 22.38 million (USD 3.18 million), increase of 11.1% compared with the same period, reflecting continuous improvements in the Company’s operational efficiency and cost management.

Quote from Min Shu, CEO of MicroAlgo:

“2025 is the year when we achieved outstanding results. We have achieved strong growth in net profit while maintaining stable cash flow and ample liquidity. These achievements fully demonstrate the robustness of the company’s core business and our continuous efforts in cost control and operational efficiency improvement. We believe that with a solid financial foundation and clear strategic direction, the company is fully prepared for sustainable growth in the future.”

The information disclosed in this press release does not purport to be complete and is qualified in its entirety by reference to the Company’s annual report on Form 20-F. The annual report, which contains the Company’s audited consolidate statements, can be accessed on the SEC’s website at http://www.sec.gov and on the Company’s investor relations website at http://ir.microalgor.com/.

About MicroAlgo Inc.

MicroAlgo Inc. (the “MicroAlgo”), a Cayman Islands exempted company, is dedicated to the development and application of bespoke central processing algorithms. MicroAlgo provides comprehensive solutions to customers by integrating central processing algorithms with software or hardware, or both, thereby helping them to increase the number of customers, improve end-user satisfaction, achieve direct cost savings, reduce power consumption, and achieve technical goals. The range of MicroAlgo’s services includes algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence services. MicroAlgo’s ability to efficiently deliver software and hardware optimization to customers through bespoke central processing algorithms serves as a driving force for MicroAlgo’s long-term development.

Safe Harbor / Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of MicroAlgo, including those set forth in the Risk Factors section of MicroAlgo’s periodic reports on Forms 20-F and 6-K filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, MicroAlgo’s expectations with respect to future performance and anticipated financial impacts of the business transaction.

MicroAlgo undertakes no obligation to update these statements for revisions or changes after the date of this release, except as may be required by law.

Recognized for innovation and measurable customer impact in automated security validation.

SAN ANTONIO, April 1, 2026 /PRNewswire/ — Frost & Sullivan is pleased to announce that Ridge Security has been recognized with the 2026 Global New Product Innovation Recognition in the Automated Security Validation industry for its outstanding achievements in innovation, strategy execution, and customer impact. This recognition highlights Ridge Security’s consistency in driving measurable outcomes, strengthening its market position, and delivering customer-centric innovation in an increasingly complex threat landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Ridge Security excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale.

“Silicon Valley-based Ridge Security helps enterprises adapt to an increasingly dynamic threat landscape through intelligent, automated, and continuous security validation. The company positions security validation as a foundational capability that not only keeps pace with emerging threats but also ensures that existing security controls remain consistently effective over time. To address the limitations of point-in-time and manual testing approaches, Ridge Security’s product design strategy emphasizes evidence-based validation that reflects real-world adversary behavior,” said Daphne Dwiputriane, Research Analyst, Frost & Sullivan.

Guided by a long-term growth strategy focused on digital innovation, AI-driven product development, and customer-centric partnerships, Ridge Security has shown its ability to adapt and lead in a rapidly evolving landscape. The company’s strategic agility and sustained investment in automated security validation and continuous threat exposure management (CTEM) have enabled it to scale effectively across global markets.

Innovation remains central to Ridge Security’s approach. Its suite of automated security validation solutions, led by its flagship RidgeBot platform, delivers continuous attack simulation, exposure discovery, and evidence-based validation aligned to real-world adversary behavior. Leveraging proprietary AI engines, RidgeBrain and RidgeGen, the platform delivers real-world attack emulation, enabling organizations to prioritize remediation based on exploitability and impact while strengthening detection and response capabilities.

“Security teams don’t need more alerts – they need proof of what can actually be exploited,” said Lydia Zhang, president & co-founder at Ridge Security. “This recognition from Frost & Sullivan validates the industry’s shift toward continuous, adversary-driven security validation and reinforces our mission to help organizations focus on the exposures that truly matter.”

Ridge Security’s strong commitment to customer experience further strengthens its position in the market. By streamlining service delivery and maintaining high levels of service availability, the company continues to meet the needs of its expanding global customer base. Its partner-led delivery model and focus on localized support have been key to delivering long-term value across diverse market segments.

Frost & Sullivan commends Ridge Security for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s vision, innovation pipeline, and customer-first culture are shaping the future of automated security validation and driving tangible results at scale.

Each year, Frost & Sullivan presents the New Product Innovation Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition identifies forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices Recognition
Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

Contact:
Ashley Shreve
E: ashley.weinkauf@frost.com

About Ridge Security
Ridge Security delivers intelligent, autonomous cybersecurity validation solutions that help organizations proactively manage risk and improve resilience. Its flagship platform, RidgeBot^®, is a leading agentic AI-based adversarial risk validation platform that supports continuous threat exposure management programs. Recognized by Gartner in the Market Guide for Adversarial Exposure Validation and honored with awards such as Top Emerging Cyber Security Company, CRN’s Tech Elite 250, and the TMCnet Cybersecurity Excellence Award, Ridge Security serves customers around the world in sectors including finance, government, telecom, and enterprise.

For more information, go to https://ridgesecurity.ai/.

Media Contacts
Monserrat Enriquez Mendoza
Ridge Security Technology Inc.
monse@ridgesecurity.ai

Dan Chmielewski
Madison Alexander PR
714-832-8716
949-231-2965
dchm@madisonalexanderpr.com

SHENZHEN, China, April 1, 2026 /PRNewswire/ — Meiwu Technology Company Limited (“WNW” or the “Company”), (NASDAQ: WNW) today announced that it will effect a reverse share split of its outstanding ordinary shares, no par value (the “Ordinary Shares”), at a ratio of 1-for-100.

Our Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on April 6, 2026. Following the reverse share split, the Ordinary Shares will continue to trade on Nasdaq under the symbol “WNW” with the new CUSIP number, G9604C131. The reverse share split is expected to lead the Company’s Ordinary Shares to trade at approximately 100 times the price per share at which it trades prior to the effectiveness of the reverse share split. The Company, however, cannot assure that the price of its Ordinary Shares after the reverse split will reflect the 1-for-100 reverse split ratio, that the price per share following the effective time of the reverse split will be maintained for any period of time, or that the price will remain above the pre-split trading price.

No fractional shares will be issued in connection with the reverse share split and all such fractional interests will be rounded up to the nearest whole number of Ordinary Shares.

The reverse share split will reduce the number of issued and outstanding shares of the Company’s Ordinary Shares from 133,042,533 to approximately 1,330,426, subject to any adjustments resulting from the treatment of the fractional shares.

On March 17, 2026, the board of directors of the Company approved the reverse share split of the Ordinary Shares, at a ratio of 1-for-100.

TranShare Corporation is acting as the exchange agent and paying agent for the reverse share split. Shareholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse share split.

TranShare Corporation will provide instructions to any shareholders with certificates regarding the process in connection with the exchange of pre-reverse share split share certificates for ownership in book-entry form or share certificates on a post-reverse share split basis. Shareholders are encouraged to contact their bank, broker or custodian with any procedural questions.

About Meiwu Technology Company Limited

Meiwu Technology Company Limited is a British Virgin Islands company incorporated on December 4, 2018. Meiwu implemented a strategic transition of its business from online sales of selected high-quality food products and short message service to the skincare industry, and currently engages in the sale of the functional skincare products through Xiamen Chunshang Health Technology Co., Ltd. (“Chunshang Xiamen”), an indirect wholly owned subsidiary of Meiwu in China.

Safe Harbor Statement

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are: the ability to manage growth; ability to identify and integrate other future acquisitions; ability to obtain additional financing in the future to fund capital expenditures; fluctuations in general economic and business conditions; costs or other factors adversely affecting our profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; a pandemic or epidemic. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in the Company’s filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Such information speaks only as of the date of this release.

Contact
Meiwu Technology Company Limited
Zhichao Yang
Email: meiwuBS@usmeiwu.com

XIAMEN, China, April 1, 2026 /PRNewswire/ — HiTek Global Inc. (Nasdaq: HKIT) (the “Company”), an information technology consulting and solutions provider, announced today that it will effect a 50-for-1 share consolidation of its Class A ordinary shares, effective April 6, 2026 (the “Share Consolidation”), in order to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Beginning with the opening of trading on April 6, 2026, the Company’s Class A ordinary shares will begin trading on the Nasdaq Capital Market on a split-adjusted basis under the same trading symbol, “HKIT,” and a new CUSIP number, G45139113.

On November 24, 2025, at the 2025 Annual General Meeting of Shareholders, the Company’s shareholders authorized the board of directors of the Company (the “Board”) to effect one or more share consolidations of the Company’s Class A ordinary shares at an aggregate cumulative ratio ranging from 1-for-40 to 1-for-5,000 within two years following the date of the meeting, with the Board having discretion to determine the specific ratio or ratios and the timing of any such share consolidation(s). On March 25, 2026, the Board approved the Share Consolidation.

Upon the Share Consolidation becoming effective, every 50 issued Class A ordinary shares of the Company, par value US$0.0001 per share, will be consolidated into one Class A ordinary share, and the par value of each Class A ordinary share will be adjusted to US$0.005. The Company’s total authorized share capital will remain unchanged at US$316,000 and will be reclassified into (i) 60,000,000 Class A ordinary shares, par value US$0.005 per share, (ii) 150,000,000 Class B ordinary shares, par value US$0.0001 per share, and (iii) 10,000,000 preference shares, par value US$0.0001 per share.

No fractional shares will be issued in connection with the Share Consolidation. Any fractional share resulting from the Share Consolidation will be rounded to the nearest whole share at the participant level.

About Hitek Global Inc.

HiTek Global Inc., headquartered in Xiamen, China, is an information technology (“IT”) consulting and solutions service provider in China. The Company operates two lines of business: (1) services for small and medium-sized businesses, consisting of Anti-Counterfeiting Tax Control System (“ACTCS”) tax devices, ACTCS services, and IT services, and (2) services for large businesses, consisting of hardware sales and software sales. The Company’s vision is to become a one-stop destination for comprehensive IT consulting and other business consulting services in China. For more information, please visit the Company’s website at http://www.xmhitek.com/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.